Cours suspendu

Communiqués Catalyst Pharmaceuticals, Inc.

Actions

CPRX

US14888U1016

Produits pharmaceutiques

Temps Différé Nasdaq Autres places de cotation 22:00:00 14/07/2026			Varia. 5j.	Varia. 1 janv.
31,49 ^USD	+0,03%		-.--%	+34,92%

03/08	Cdp vise de nouvelles acquisitions dans la défense après l'opération T-Defence - sources	RE
03/08	La nouvelle vie de la CDP, moteur des entreprises mondiales	AN

Communiqués

16/07	Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals	AQ
30/06	Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses	GL
24/06	Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX	BU
11/05	Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results	GL
10/05	Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX	BU
07/05	Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast	GL
07/05	CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders	BU
07/05	Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.	GL
07/05	Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease	AQ
28/04	Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026	GL
10/03	Catalyst Pharmaceuticals : Corporate Presentation	PU
06/03	Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference	GL
25/02	Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance	GL
25/02	Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance	AQ
24/02	Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference	GL
11/02	Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026	GL
08/01	Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies	GL
08/01	Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies	AQ
06/01	The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit	AQ
05/01	The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)	GL
15/12	Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference	GL
24/11	Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference	GL
19/11	Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™	GL
18/11	Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference	GL
05/11	Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update	GL